返回
TransThera Sciences (Nanjing), Inc.（02617.HK）价格
02617.HK 股价走势图
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$0
0%
$0
休市： Jan 28, 16:00:00 HKT
暂无数据Follow-Up Questions
TransThera Sciences (Nanjing), Inc. 的关键财务报表是什么？
02617.HK 的关键财务比率是什么？
TransThera Sciences (Nanjing), Inc. 的收入按细分市场或地理位置如何划分？
TransThera Sciences (Nanjing), Inc. 是否盈利？
TransThera Sciences (Nanjing), Inc. 有负债吗？
TransThera Sciences (Nanjing), Inc. 的流通股有多少？
关键数据
前收盘价
--
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
1.7M
每股收益（TTM）
-0.66
股息收益率
--
市值
--
什么是 TRANSTHERA-B？
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.